Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, ...

Stereotaxis gains CE Mark for MAGiC catheter, boosting revenue with high margins. FDA approval expected soon. Click here to ...

Stereotaxis receives its first order for the next-generation robotic system, GenesisX. The company expects a full commercial launch in the coming months. ST. LOUIS, Feb. 03, 2025 (GLOBE NEWSWIRE ...

ST. LOUIS, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it has ...

Stereotaxis announced that it has received European CE Mark approval for its MAGiC™ ablation catheter, marking a significant step in advancing robotic technology in electrophysiology.

Stereotaxis (STXS) announced that it received European CE Mark approval for the MAGiC ablation catheter. This approval is a significant milestone for Stereotaxis and for the community of ...

Detailed price information for Stereotaxis Inc (STXS-A) from The Globe and Mail including charting and trades.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

ST. LOUIS, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it ...

Stereotaxis receives its first order for the next-generation robotic system, GenesisX. The company expects a full commercial launch in the coming months. ST. LOUIS, Feb. 03, 2025 (GLOBE NEWSWIRE) -- ...